Asset Details
Do you wish to reserve the book?
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
Do you wish to request the book?
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
2015
Overview
Expression of oestrogen receptor (ESR1) determines whether a breast cancer patient receives endocrine therapy, but does not guarantee patient response. The molecular factors that define endocrine response in ESR1-positive breast cancer patients remain poorly understood. Here we characterize the DNA methylome of endocrine sensitivity and demonstrate the potential impact of differential DNA methylation on endocrine response in breast cancer. We show that DNA hypermethylation occurs predominantly at oestrogen-responsive enhancers and is associated with reduced ESR1 binding and decreased gene expression of key regulators of ESR1 activity, thus providing a novel mechanism by which endocrine response is abated in ESR1-positive breast cancers. Conversely, we delineate that ESR1-responsive enhancer hypomethylation is critical in transition from normal mammary epithelial cells to endocrine-responsive ESR1-positive cancer. Cumulatively, these novel insights highlight the potential of ESR1-responsive enhancer methylation to both predict ESR1-positive disease and stratify ESR1-positive breast cancer patients as responders to endocrine therapy.
The molecular factors influencing patient response to endocrine therapy are poorly understood. Here Stone
et al.
characterize the DNA methylome of endocrine response and show that methylation of oestrogen receptor-associated enhancers underpins endocrine sensitivity in human breast cancer.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Pub. Group
Subject
/ Adult
/ Aged
/ Antineoplastic Agents, Hormonal - therapeutic use
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Carcinoma, Ductal, Breast - drug therapy
/ Carcinoma, Ductal, Breast - genetics
/ Carcinoma, Ductal, Breast - metabolism
/ Carcinoma, Lobular - drug therapy
/ Carcinoma, Lobular - genetics
/ Carcinoma, Lobular - metabolism
/ Chromatin Immunoprecipitation
/ DNA
/ Drug Resistance, Neoplasm - genetics
/ Enhancer Elements, Genetic - genetics
/ Estrogen Receptor alpha - genetics
/ Estrogen Receptor alpha - metabolism
/ Female
/ Humanities and Social Sciences
/ Humans
/ Multiplex Polymerase Chain Reaction
/ Science
